Demographic and disease-related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis.
biomarker
brain atrophy
disease-modifying therapies
multiple sclerosis
neurofilament light chain
progressive multiple sclerosis
relapsing-remitting multiple sclerosis
Journal
Brain and behavior
ISSN: 2162-3279
Titre abrégé: Brain Behav
Pays: United States
ID NLM: 101570837
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
07
11
2022
received:
21
09
2022
accepted:
13
12
2022
pubmed:
28
12
2022
medline:
21
1
2023
entrez:
27
12
2022
Statut:
ppublish
Résumé
Neurofilament light (NfL) levels reflect inflammatory disease activity in multiple sclerosis (MS), but it is less clear if NfL also can serve as a biomarker for MS progression in treated patients without relapses and focal lesion accrual. In addition, it has not been well established if clinically effective treatment re-establishes an age and sex pattern for cerebrospinal fluid NfL (cNfL) as seen in controls, and to what degree levels are affected by disability level and magnetic resonance imaging (MRI) atrophy metrics. We included subjects for whom cNfL levels had been determined as per clinical routine or in clinical research, classified as healthy controls (HCs, n = 89), MS-free disease controls (DCs, n = 251), untreated MS patients (uMS; n = 296), relapse-free treated MS patients (tMS; n = 78), and ProTEct-MS clinical trial participants (pMS; n = 41). Using linear regression, we found a positive association between cNfL and age, as well as lower concentrations among women, in all groups, except for uMS patients. In contrast, disability level in the entire MS cohort, or T1 and T2 lesion volumes, brain parenchymal fraction, thalamic fraction, and cortical thickness in the pMS trial cohort, did not correlate with cNfL concentrations. Furthermore, the cNfL levels in tMS and pMS groups did not differ. In participants with MS lacking signs of inflammatory disease activity, disease modulatory therapy reinstates an age and sex cNfL pattern similar to that of control subjects. No significant association was found between cNfL levels and clinical worsening, disability level, or MRI metrics.
Sections du résumé
BACKGROUND
Neurofilament light (NfL) levels reflect inflammatory disease activity in multiple sclerosis (MS), but it is less clear if NfL also can serve as a biomarker for MS progression in treated patients without relapses and focal lesion accrual. In addition, it has not been well established if clinically effective treatment re-establishes an age and sex pattern for cerebrospinal fluid NfL (cNfL) as seen in controls, and to what degree levels are affected by disability level and magnetic resonance imaging (MRI) atrophy metrics.
METHODS
We included subjects for whom cNfL levels had been determined as per clinical routine or in clinical research, classified as healthy controls (HCs, n = 89), MS-free disease controls (DCs, n = 251), untreated MS patients (uMS; n = 296), relapse-free treated MS patients (tMS; n = 78), and ProTEct-MS clinical trial participants (pMS; n = 41).
RESULTS
Using linear regression, we found a positive association between cNfL and age, as well as lower concentrations among women, in all groups, except for uMS patients. In contrast, disability level in the entire MS cohort, or T1 and T2 lesion volumes, brain parenchymal fraction, thalamic fraction, and cortical thickness in the pMS trial cohort, did not correlate with cNfL concentrations. Furthermore, the cNfL levels in tMS and pMS groups did not differ.
CONCLUSIONS
In participants with MS lacking signs of inflammatory disease activity, disease modulatory therapy reinstates an age and sex cNfL pattern similar to that of control subjects. No significant association was found between cNfL levels and clinical worsening, disability level, or MRI metrics.
Identifiants
pubmed: 36573731
doi: 10.1002/brb3.2873
pmc: PMC9847611
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2873Subventions
Organisme : University of Ostrava
ID : CZ.02.2.69/0.0/0.0/16_018/0002635
Organisme : GeNeuro S.A
ID : GeNeuro GNC-401/EudraCT number:
Organisme : GeNeuro S.A
ID : 2019-004822-15
Organisme : Swedish MRC
ID : 2020-02700
Organisme : Hjärnfonden
ID : FO2021-0277
Informations de copyright
© 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
Références
Nat Rev Dis Primers. 2018 Nov 8;4(1):43
pubmed: 30410033
Mult Scler. 2013 Apr;19(4):436-42
pubmed: 22917689
Neuroimage. 2012 Feb 15;59(4):3774-83
pubmed: 22119648
Lancet Neurol. 2022 Mar;21(3):246-257
pubmed: 35182510
Neurol Neuroimmunol Neuroinflamm. 2020 Nov 10;8(1):
pubmed: 33172960
Mult Scler. 2018 Jul;24(8):1039-1045
pubmed: 28537100
Rev Neurosci. 2021 Feb 17;32(6):573-595
pubmed: 33594840
JCI Insight. 2022 Aug 8;7(15):
pubmed: 35737460
JAMA Neurol. 2019 Sep 01;76(9):1035-1048
pubmed: 31206160
BMJ Neurol Open. 2021 Jun 16;3(1):e000143
pubmed: 34223154
J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):1059-1067
pubmed: 31123141
Aging Clin Exp Res. 2022 Feb;34(2):331-339
pubmed: 35018623
Mult Scler. 2013 Nov;19(13):1802-9
pubmed: 23695446
Ann Clin Transl Neurol. 2020 Dec;7(12):2508-2523
pubmed: 33146954
Eur J Neurol. 2015 Jun;22(6):960-6
pubmed: 25786797
Mult Scler J Exp Transl Clin. 2021 Dec 06;7(4):20552173211060337
pubmed: 34900328
Sci Rep. 2020 Nov 23;10(1):20350
pubmed: 33230211
Epidemiology. 2019 Mar;30(2):230-233
pubmed: 30721167
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Neurol Neuroimmunol Neuroinflamm. 2021 Sep 8;8(6):
pubmed: 34497102
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Brain. 2013 Dec;136(Pt 12):3609-17
pubmed: 24142147
J Neurol. 2011 May;258(5):882-8
pubmed: 21197541
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
Neurology. 2020 Sep 8;95(10):436-444
pubmed: 32675076
Brain. 2021 Nov 29;144(10):2954-2963
pubmed: 34180982
Brain Behav. 2023 Jan;13(1):e2873
pubmed: 36573731
Ann Clin Transl Neurol. 2020 Jan;7(1):139-143
pubmed: 31893563
Ann Neurol. 2015 Nov;78(5):710-21
pubmed: 26239536
Neuroimage. 2012 Aug 15;62(2):774-81
pubmed: 22248573